Immunostimulatory biodegradable implants containing the adjuvant Quil-A - Part II: In vivo evaluation

Journal of Drug Targeting

Volumn 16, Issue 3, 2008, Pages 224-232

  Myschik, Julia ^a   Mcburney, Warren ^a   Hennessy, Tania ^a   Phipps Green, Amanda ^a   Rades, Thomas ^a   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CD8+ T cells; Colloidal particles; Immune response; Implant; Quil A; Sustained release system

Indexed keywords

ADJUVANT; ANTIGEN; GAMMA INTERFERON; LIPID; LIPOSOME; OVALBUMIN; QUIL A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; DELAYED-ACTION PREPARATIONS; IMMUNOGLOBULIN G; INTERFERON TYPE II; MALE; MICE; MICE, INBRED C57BL; OVALBUMIN; SAPONINS; VACCINES;

EID: 41549085640     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701848886     Document Type: Article

References (32)

1. Anderson, JM and Shive, MS (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 28, pp. 5-24.
2. Bangham, AD, Horne, RW, Glauert, AM, Dingle, JT and Lucy, JA (1962) Action of saponin on biological cell membranes. Nature, 196, pp. 952-955.
3. Barnden, MJ, Allison, J., Heath, WR and Carbone, FR (1998) Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol, 76, pp. 34-40.
4. Barr, IG, Sjolander, A. and Cox, JC (1998) ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev, 32, pp. 247-271.
5. Bramwell, VW and Perrie, Y. (2005) Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst, 22, pp. 151-214.
6. Cox, JC and Coulter, AR (1997) Adjuvants-a classification and review of their modes of action. Vaccine, 15, pp. 248-256.
7. Dalsgaard, K. (1974) Saponin adjuvants. III. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch Gesamte Virusforsch, 44, pp. 243-254.
8. Dash, AK and Cudworth 2nd, GC (1998) Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods, 40, pp. 1-12.
9. De Boer, RJ, Homann, D. and Perelson, AS (2003) Different dynamics of CD4+ and CD8+T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol, 171, pp. 3928-3935.
10. Demana, PH, Fehske, C., White, K., Rades, T. and Hook, S. (2004) Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunol Cell Biol, 82, pp. 547-554.
11. Friede, M. and Aguado, MT (2005) Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv Drug Deliv Rev, 57, pp. 325-331.
12. Gamvrellis, A., Leong, D., Hanley, JC, Xiang, SD, Mottram, P. and Plebanski, M. (2004) Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol, 82, pp. 506-516.
13. Gupta, RK (1998) Aluminium compounds as vaccine adjuvants. Adv Drug Deliv Rev, 32, pp. 155-172.
14. Heeg, K., Kuon, W. and Wagner, H. (1991) Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: Immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur J Immunol, 21, pp. 1523-1527.
15. Kemp, JM, Kajihara, M., Nagahara, S., Sano, A., Brandon, M. and Lofthouse, S. (2002) Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses. Vaccine, 20, pp. 1089-1098.
16. Kensil, CR (1996) Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst, 13, pp. 1-55.
17. Kersten, GFA and Crommelin, DJA (2003) Liposomes and ISCOMs. Vaccine, 21, pp. 915-920.
18. Li, M., Davey, GM, Sutherland, RM, Kurts, C., Lew, AM, Hirst, C., Carbone, FR and Heath, WR (2001) Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol, 166, pp. 6099-6103.
19. Lipford, GB, Wagner, H. and Heeg, K. (1994) Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells. Vaccine, 12, pp. 73-80.
20. Lofthouse, SA, Kajihara, M., Nagahara, S., Nash, A., Barcham, GJ, Sedgmen, B., Brandon, MR and Sano, A. (2002) Injectable silicone implants as vaccine delivery vehicles. Vaccine, 20, pp. 1725-1732.
21. Medlicott, NJ and Tucker, IG (1999) Pulsatile release from subcutaneous implants. Adv Drug Deliv Rev, 38, pp. 139-149.
22. Parkin, J. and Cohen, B. (2001) An overview of the immune system. Lancet, 357, pp. 1777-1789.
23. Preis, I. and Langer, RS (1979) A single-step immunization by sustained antigen release. J Immunol Methods, 28, pp. 193-197.
24. Rao, M. and Alving, CR (2000) Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv Drug Deliv Rev, 41, pp. 171-188.
25. Silva, DRM, Joazeiro, PP, Duek, EAR and Alberto-Rincon, MC (2006) Subdermal implants of poly(-lactic acid) with plasticizer: An ultrastructural study in rats. J Biomater Sci Polym Ed, 17, pp. 177-185.
26. Singh, M. and O'Hagan, DT (2002) Recent advances in vaccine adjuvants. Pharm Res, 19, pp. 715-728.
27. Sjölander, A., Cox, JC and Barr, IG (1998) ISCOMs: An adjuvant with multiple functions. J Leukoc Biol, 64, pp. 713-723.
28. Toes, REM, Blom, RJJ, Offringa, R., Kast, WM and Melief, CJM (1996) Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol, 156, pp. 3911-3918.
29. Walduck, AK, Opdebeeck, JP, Benson, HE and Prankerd, R. (1998) Biodegradable implants for the delivery of veterinary vaccines: Design, manufacture and antibody response in sheep. J Control Release, 51, pp. 269-280.
30. White, K., Rades, T., Kearns, P., Toth, I. and Hook, S. (2006) Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A. Pharm Res, 23, pp. 1473-1481.
31. Yang, C-P, Sparshott, SM, Duffy, D., Garside, P. and Bell, EB (2006) The phenotype and survival of antigen-stimulated transgenic CD4 T cells in vivo: The influence of persisting antigen. Int Immunol, 18, pp. 515-523.
32. Zinkernagel, RM, Ehl, S., Aichele, P., Oehen, S., Kuendig, T. and Hengartner, H. (1997) Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity. Immunol Rev, 156, pp. 199-209.